(vianews) - equasens (eqs.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| equasens (eqs.pa) | €51.30 | 1.89% | 27.25% |
| ucb (ucb.br) | €120.35 | 1.13% | 3.8% |
| ipsen (ipn.pa) | €110.30 | 1.1% | 17.3% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. equasens (eqs.pa)
1.89% forward dividend yield and 27.25% return on equity
equasens société anonyme provides healthcare it solutions in europe. it offers id. patient, a business software; id. mobility, a back-office management software; pandalab pro, an instant messaging solution; id. vente, an has-certified drug database; id. commande, an order management module; dispensing robots; services ségur id; id. dosage, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; visiodroits module; and website connector. the company also provides id. desk, an informative and interactive dashboard; id. up!, a real-time monitoring and control application of id management software; id. easyq, a queue management solution; miaterapia; id. show, an application for managing real-time communications on pharmacy screens; pharmaweb; tsgatepro; lmo, a dispensary business software; and lgo, a dispensary management software. in addition, it offers domilink had software; mobisoins mobility tool; memorialis, support software for alzheimer's monitoring teams; hospilink, an hospital information system applications; hospilink dpi, a computerized patient file; hospilink lookup big data; enephro solutions; noviacare solutions; kap&link2, a contact chip card reader terminal and nfc reader; es-kap-ad, a connected nomadic tool incorporating software; kap-inside, a mobile terminal; and ti-kap allowing access to contact and contactless cards. further, the company provides authenticator, a patented authentication system; kap'teur by kapelse, a patented universal sensor; expressvitale; médistory, that automates the transfer of invoicing to the healthcare professional's accounting. additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. the company was incorporated in 1996 and is headquartered in villers-les-nancy, france. equasens société anonyme is a subsidiary of marque verte sante.
earnings per share
as for profitability, equasens has a trailing twelve months eps of €3.2.
pe ratio
equasens has a trailing twelve months price to earnings ratio of 16.03. meaning, the purchaser of the share is investing €16.03 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.25%.
moving average
equasens's worth is under its 50-day moving average of €51.40 and way below its 200-day moving average of €63.76.yearly top and bottom value
equasens's stock is valued at €51.30 at 07:30 est, way under its 52-week high of €85.80 and way higher than its 52-week low of €46.15.
dividend yield
as stated by morningstar, inc., the next dividend payment is on jul 3, 2023, the estimated forward annual dividend rate is 1.15 and the estimated forward annual dividend yield is 1.89%.
more news about equasens.
2. ucb (ucb.br)
1.13% forward dividend yield and 3.8% return on equity
ucb sa, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. the company's primary products include cimzia for inflammatory tnf mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; vimpat, keppra, and briviact for epilepsy; neupro for parkinson's disease and restless legs syndrome; nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and zyrtec and xyzal for allergies. it also offers evenity for the treatment of osteoporosis in postmenopausal women; bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and fintepla to treat dravet syndrome. in addition, the company is involved in developing rozanolixizumab and zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat cdkl5 deficiency disorder; doxecitine for tk2 deficiency disorder; staccato alprazolam for stereotypical prolonged seizures; bepranemab to treat alzheimer's disease; minzasolmin and ucb0222 for parkinson's disease; and ucb1381 and ucb9741 for atropic dermatitis. further, it engages in contract manufacturing activities. ucb sa has collaboration agreements with amgen, biogen, roche/genentech, novartis, and otsuka. the company was incorporated in 1925 and is headquartered in brussels, belgium.
earnings per share
as for profitability, ucb has a trailing twelve months eps of €1.76.
pe ratio
ucb has a trailing twelve months price to earnings ratio of 68.38. meaning, the purchaser of the share is investing €68.38 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.8%.
yearly top and bottom value
ucb's stock is valued at €120.35 at 07:30 est, below its 52-week high of €122.60 and way higher than its 52-week low of €65.40.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ucb's stock is considered to be oversold (<=20).
more news about ucb.
3. ipsen (ipn.pa)
1.1% forward dividend yield and 17.3% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. its product pipeline comprises cabometyx + atezolizumab, which is in phase iii clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and taverik, which is in phase iii for the treatment of second line follicular lymphoma; bylvay, which is in phase iii for the treatment of biliary atresia; dysport, which is in phase iii clinical trial for the treatment of chronic and episodic migraine; fidrisertib, which is in phase ii clinical trial for the treatment of fibrodysplasia ossificans progressiva; elafibranor, which is in phase ii for the treatment of primary sclerosing cholangitis, as well as ipn60250; ipn10200, which is in phase ii for the treatment of longer-acting neurotoxin aesthetics and therapeutics; ipn60210, which is in phase i clinical trial for the treatment of relapsed/refractory multiple myeloma; and ipn60260 for the treatment of viral cholestatic disease and is in phase i clinical trial. the company also offers somatuline, decapeptyl, cabometyx, onivyde, tazverik, and other oncology products; dysport and other neurosciences products; and bylvay, nutropinaq, increlex, and sohonos for rare diseases. the company was founded in 1929 and is based in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €7.4.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 14.91. meaning, the purchaser of the share is investing €14.91 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.3%.
volatility
ipsen's last week, last month's, and last quarter's current intraday variation average was a negative 0.72%, a positive 0.05%, and a positive 1.08%.
ipsen's highest amplitude of average volatility was 0.72% (last week), 1.11% (last month), and 1.08% (last quarter).
more news about ipsen.